Finally, in PIONEER 8, patients were randomised to oral semaglutide 3, 7 or 14 mg once daily or placebo as an add-on to basal, premixed or basal-bolus insulin with or without metformin [11]
CrossRef Metabolic biomarkers predict subclinical cardiac remodeling in obese individuals Mengjie Hu, Huawei Wang, Zixuan Mei, Cheng Gong, Lan Lan, Zixuan Ma, Binhao Zhang, Haomiao Fan, Yuqing Zhang, He Wang, Wanshun Chun, Dingyu Pan, Jianliang Zhou, Zhen Li Metabolism and Target Organ Damage .2026;[Epub] CrossRef Association between antihypertensive medications and hepatocellular carcinoma risk in individuals with metabolic dysfunctionassociated steatotic liver disease (MASLD) without cirrhosis Hao-Chien Hung, Po-Jung Hsu, Yin Lai, Wei-Chen Lee, Chen-Fang Lee Annals of Hepatology .2026
The study did not investigate the effects of ceasing to use a GLP-1 medication, but previous human investigations have found that regaining weight is almost inevitable
10.1016/j.cellsig.2008.06.004 92 KelesI.BozkurtM
